High Court Won’t Take Up Off-Label Case; Other FCA Issues On Docket
Executive Summary
While the Supreme Court announced this week that it won’t hear a case related to off-label billings, other False Claims Act-related suits may still be on the docket.
You may also be interested in...
Mid-Year Enforcement Roundup: Focus On Opioids, As Other Areas Lag
A recent report from law firm Gibson Dunn seems to show that the Trump administration, while aggressively pursuing opioid enforcement actions, slowed down enforcement in other areas during the first half of 2018. But important case-law developments continue.
What Did The Government Know, And When Did Know It? US Supreme Court Seeks Views On False-Claims Case
The US Solicitor General was asked to weigh in on Gilead's petition asking the high court to clarify application of its Escobar decision. Trade groups say FDA, not a jury, should decide whether a company has complied with the Food, Drug and Cosmetic Act.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.